Eli Hurvitz

Eliyahu “Eli” Hurvitz (April 20, 1932–November 21, 2011) was an Israeli industrialist, executive and public figure who helped shape the country’s modern industrial economy. As chief executive of Teva from 1976 to 2002 and chairman of its board until 2010, he led the company’s transformation from an Israeli pharmaceutical group into a global leader in generic medicines.

Hurvitz’s importance extends beyond the company he managed. He helped demonstrate that an Israeli enterprise could combine science, manufacturing, exports and professional management on an international scale. He also served in senior public, financial, academic and civic roles, supporting the development of Israel’s industrial base, medical education and public institutions.

From Jerusalem and Tel Aviv to industry

Hurvitz was born in Jerusalem to Zvi and Tziporah Hurvitz. In 1934, his family moved to Tel Aviv, where he attended the Carmel School and later Herzliya Hebrew High School. During Israel’s War of Independence, he temporarily interrupted his studies with his classmates to take part in the national effort, then returned to school and completed his matriculation examinations.

He joined the Nahal and was among the founders of Kibbutz Tel Katzir. In 1953 he married Dalia Solomon, whose family was associated with Assia Pharmaceuticals. While studying economics at the Hebrew University of Jerusalem, Hurvitz began working at Assia. He started in the laboratory and gradually moved into office work, pricing, accounting and management. This progression gave him practical knowledge of the entire industrial chain, from production and labor relations to finance and corporate strategy.

Building Teva

In 1964, Assia merged with Zori. Hurvitz managed negotiations with Zori’s employees; some received compensation while others were integrated into Assia’s operations. The successful transition contributed to his appointment as Assia’s manager and showed his ability to manage organizational change while addressing the human consequences of industrial consolidation.

In 1969, Assia acquired a controlling interest in Teva, and in 1976 the three companies were merged into Teva Pharmaceutical Industries. Hurvitz became chief executive of the Teva group and received the Industry Prize in the chemistry category that same year. Over the next 26 years, he developed the organizational and commercial foundations that enabled Teva to expand beyond Israel and become a major international producer of generic medicines.

The significance of this achievement reached far beyond Teva’s balance sheet. For many years, the company was one of the clearest examples of Israel’s ability to build a globally competitive, knowledge-intensive enterprise. Its growth created employment and professional opportunities in pharmaceuticals, chemistry, engineering, research, marketing and management. The generic medicines Teva produced and distributed also helped widen access to affordable treatments in health systems around the world.

In 2002, when he reached the age of 70, Hurvitz stepped down as chief executive and handed leadership to Israel Makov. He remained chairman of the board until 2010. The orderly transition reflected the institutional strength he had helped build and marked a new stage in Teva’s development as an international company.

Public service and economic leadership

In the mid-1970s, Hurvitz served as director general of the Israel Export Institute, leading it from 1974 to 1978. He worked to strengthen the connection between Israeli manufacturers and overseas markets. In 1981 he became president of the Manufacturers’ Association of Israel, representing industry in national discussions about exports, employment, growth and economic policy.

Hurvitz also served on the board of Bank Leumi and was appointed its chairman in May 1986, after the bank-stock crisis had placed Israel’s financial system under severe strain. He divided his time between Bank Leumi and Teva. During his tenure, the board approved reductions in some executive salaries. In January 1987, amid pressure to examine the severance arrangements of Ernest Japhet, Hurvitz resigned from the chairmanship.

His later public roles included chairing the Jerusalem Development Authority from 1989 to 1992, serving on the Bank of Israel’s advisory committee, and holding directorships in several companies and institutions. From 1989 to 1995 he chaired the executive committee of the Weizmann Institute of Science. He was also a member of Tel Aviv University’s board of governors and became chairman of the Israel Democracy Institute in 2002.

These positions reflected his view that Israel’s economic future depended on more than individual companies. Scientific research, higher education, public administration, financial institutions and industrial leadership had to reinforce one another. His work helped connect those spheres and brought the experience of large-scale management into national conversations about development.

Medicine, education and philanthropy

After leaving Teva’s day-to-day management, Hurvitz remained active in innovative medical initiatives. He was among the investors and founders of the Faculty of Medicine in Safed, an institution intended to strengthen medical education and healthcare infrastructure in northern Israel. The project linked his industrial experience with a long-term investment in professional training and regional development.

Hurvitz received honorary doctorates from the Technion–Israel Institute of Technology, the Weizmann Institute of Science, Ben-Gurion University of the Negev, Tel Aviv University and Bar-Ilan University. In 2002, he received the Israel Prize for lifetime achievement and a special contribution to society and the State. In 2011, he received an honorary fellowship from Ariel University Center in recognition of his contribution to high-technology industry, the economy and Israeli society.

He also participated in public discussions about economic and national policy. Although he did not seek political office and preferred to describe himself as a business manager rather than a politician, he spoke about poverty reduction, economic reform, labor relations and security. In 2006, after the Second Lebanon War, he joined the Shahak Committee established by Defense Minister Amir Peretz. The committee was dissolved before it could complete its work.

An institutional legacy

After Hurvitz’s death, the Caesarea Economic Policy Planning Forum of the Israel Democracy Institute was renamed the Eli Hurvitz Conference on Economics and Society. The conference continues to address major questions in Israel’s economy and society, including growth, productivity, industry, inequality and social policy. His name is therefore connected not only with past achievement but also with continuing public deliberation.

In 2013, the Dalia and Eli Hurvitz Foundation was established to support initiatives in healthcare, education, the arts and services for older people. The foundation carries forward a broad understanding of social investment: strengthening people and institutions as well as pursuing immediate economic results. Kfar Saba Municipality also commemorated him by naming a street after him.

Hurvitz died on November 21, 2011, from sepsis and was buried at Givat HaShlosha. He was survived by his wife, Dalia, three children and grandchildren.

Why Eli Hurvitz belongs in Moreshet

Eli Hurvitz merits a prominent place in Moreshet because his life joined individual initiative with institution-building. He led Teva through the transformation that made it a globally significant pharmaceutical company, strengthening Israel’s industrial capabilities, export economy and reputation as a center of scientific and business innovation.

His influence also reached medicine, higher education, scientific research, banking, public policy and philanthropy. The conference and foundation that bear his name continue to invest in discussion, knowledge and community life. For these reasons, preserving his story on Moreshet.com means more than recording the career of a successful executive. It preserves an important chapter in the Jewish and Israeli heritage of building a future through knowledge, enterprise, public responsibility and sustained investment in society.